Chimerix (CMRX) Posts Mixed Q4 Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/3/2026

1. CRWD
2. REGN
3. LITE
4. AAPL
5. ABBV
6. MRVL
7. CL
8. LYB
9. TFII
10. ORCL

Go back to Chimerix (CMRX) Posts Mixed Q4 Results

Chimerix Announces Fourth Quarter and Full Year 2014 Financial Results

March 6, 2015 7:00 AM EST

DURHAM, N.C., March 6, 2015 (GLOBE NEWSWIRE) -- Chimerix, Inc. (Nasdaq: CMRX), a biopharmaceutical company developing novel, oral antivirals in areas of high unmet medical need, today reported financial results for the fourth quarter and full year 2014.

M. Michelle Berrey, MD, MPH, President and CEO of Chimerix, said, "The past year was one of significant growth and progress for Chimerix. As we look forward in 2015, we are focused on completing enrollment of the SUPPRESS trial of brincidofovir for the prevention of CMV, preparing for its expected NDA filing, and continuing our pre-launch initiatives.... More